Celator Pharmaceuticals, Inc. Reaches 75 Percent Enrollment Milestone In Phase 3 Study Of CPX-351  
6/4/2014 8:58:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EWING, N.J., June 4, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has achieved 75% enrollment in the Company's ongoing Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML). The planned enrollment for the study is 300 patients.

Help employers find you! Check out all the jobs and post your resume.